KYTX Stock Analysis: Buy, Sell, or Hold?
KYTX - Kyverna Therapeutics, Inc. Common Stock
$8.02
0.25 (3.22%)
▲
5d:
-17.15%
30d:
+1.91%
90d:
-15.49%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
27d
Get Alerted When KYTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KYTX is down 17.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KYTX is down 17.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: KYTX is currently trading at $8.02, which is considered slightly low relative to its 30-day fair value range of $7.75 to $9.05.
Technical Outlook: Technically, KYTX is showing sideways momentum. Immediate support is located at $7.62, while resistance sits at $10.29. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: KYTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $30.40 (+291.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KYTX is showing sideways momentum. Immediate support is located at $7.62, while resistance sits at $10.29. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: KYTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $30.40 (+291.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.75 -
$9.05
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 291.2% below Wall St target ($30.40)
- WARNING: Recommendation downgraded due to -17.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$7.75 -
$9.05
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.62
Resistance Level
$10.29
Current Trend
Sideways
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.63
Wall Street Target
$30.40
(+291.2%)
Share & Embed Analysis
Last updated: July 14, 2026 2:49 PM ET
Data refreshes hourly during market hours. Next update: 3:49 PM
Data refreshes hourly during market hours. Next update: 3:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 58 HOLD |
